TABLE 3.

MORTALITY AFTER BRONCHIOLITIS OBLITERANS SYNDROME IS UNAFFECTED BY POST–BRONCHIOLITIS OBLITERANS SYNDROME TREATMENTS

Treatment	% N	HR	95% CI	P Value
Nissen fundoplication	11 (10)	1.52	0.63–3.67	0.35
Alemtuzumab	13 (12)	1.37	0.58–3.24	0.47
Antithymocyte globulin	37 (35)	1.25	0.69–2.29	0.46
Azithromycin	58 (55)	1.44	0.78–2.65	0.24

Definition of abbreviations: CI = confidence interval; HR = hazard ratio.